Last updated: July 11, 2026
Executive summary:
Celgene Corporation v. Hetero Labs Limited (D.N.J.) is a Hatch-Waxman patent infringement dispute filed in 2018 and docketed as 2:18-cv-17463. The case centers on whether Hetero’s proposed generic product infringes Celgene’s listed patents for an oncology regimen. The litigation posture indicates active disputes over validity and infringement, with motions practice proceeding after filing and later case management activity. The consolidated value for licensing and generic entry risk depends on (1) which specific Celgene patents were asserted, (2) claim construction and noninfringement findings, and (3) whether Hetero’s Paragraph IV certifications triggered any exclusivity or launch stay effects tied to Orange Book-listed patents.
What is the case background for Celgene Corporation v. Hetero Labs Limited (2:18-cv-17463)?
Case identifier: Celgene Corporation v. Hetero Labs Limited, 2:18-cv-17463.
Court: U.S. District Court for the District of New Jersey.
Filing year: 2018.
Why this matters in generics: Hatch-Waxman paragraph IV litigation typically maps to a specific Orange Book patent set for a reference listed drug (RLD). Celgene’s asserted patents are the gating assets for generic launch timing and potential settlement.
What patents are typically at issue in Celgene-Hetero Hatch-Waxman cases?
In Celgene-originated brand-to-generic disputes, the asserted patent set commonly includes:
- composition-of-matter patents for the active ingredient or salts
- formulation patents (e.g., dosing form, excipients, particle/solid-state, polymorph)
- method-of-use patents tied to specific therapeutic regimens
- manufacturing and process patents
Litigation structure: These disputes usually include claims for direct infringement and, depending on the record, induced/contributory infringement, paired with invalidity challenges under 35 U.S.C. §§ 101/102/103/112 and noninfringement defenses.
Which drug and Orange Book patents are implicated in 2:18-cv-17463?
Featured snippet answer: The case is a Hatch-Waxman patent dispute tied to Celgene’s Orange Book-listed patents, with Hetero bringing a generic development pathway that triggered Celgene’s infringement action.
Patent identification and list mapping: The case number alone does not identify the asserted patents or the specific Orange Book listing. A complete patent-by-patent mapping requires the complaint and the Orange Book reference product/patent list for the relevant RLD.
What happens procedurally in a Paragraph IV Hatch-Waxman suit like 2:18-cv-17463?
Typical sequence:
- Generic filer submits an ANDA with paragraph IV certifications to listed patents.
- Brand owner sues within statutory deadlines for infringement.
- Courts handle:
- early motion practice (pleadings, jurisdiction, venue)
- invalidity and infringement contentions
- claim construction (Markman hearing)
- summary judgment
- If the case does not resolve before patent expiry, adjudication affects damages and launch timing.
Settlement risk window: Settlement often occurs after claim construction or after the first major dispositive rulings, when infringement and validity probabilities crystallize.
How strong is Celgene’s patent estate in this case?
Featured snippet answer: The strength assessment depends on which specific Celgene patents were asserted and the court’s construction and disposition on infringement and invalidity. Without the complaint’s asserted list and the court’s rulings, the patent strength cannot be quantified.
What determines infringement strength in generic product disputes?
- whether the accused product meets all claim limitations
- how “critical” claim terms are construed
- whether design-around changes fall within or outside the claim scope
What determines validity strength?
- novelty and obviousness under §§ 102 and 103
- enablement and written description under § 112
- subject-matter eligibility under § 101 (especially for method claims)
Which claims are most likely asserted in Celgene generic patent litigation?
In Celgene’s portfolio disputes, the asserted claim types usually fall into three buckets:
- Composition/formulation claims: targeted at the drug’s dosing form and formulation attributes.
- Method-of-use claims: targeted at administration schedules, patient populations, dosing sequences, or response endpoints.
- Manufacturing/process claims: targeted at synthesis, purification, or solid-state control.
Business impact:
- composition/formulation claims tend to block broad generics
- method-of-use claims can be easier to design around by changing labeling, though labeling carve-outs are constrained by FDA and statutory carve-outs
What is the litigation timeline for 2:18-cv-17463 (key events)?
A complete timeline requires docket event dates (complaint filing date, service, scheduling order dates, claim construction date, summary judgment rulings, trial dates, settlement or dismissal). Those dates are not included in the provided prompt.
What is the Paragraph IV status and how does it affect generic launch risk?
Featured snippet answer: Paragraph IV suits trigger an automatic 30-month stay of FDA approval if filed within the statutory window, unless resolved earlier by final court decision or settlement.
Launch risk framework:
- If the court finds infringement and does not invalidate asserted patents, generic entry is blocked until expiration.
- If claims are held invalid or not infringed, generic can launch immediately (subject to FDA approval and any remaining injunctions).
- If the parties settle, launch is governed by settlement terms (often dates, product-specific covenants, and royalty/technology-transfer provisions).
What defenses does Hetero Labs typically raise in these cases?
In Celgene brand litigation, generic defendants typically assert:
- noninfringement (no literal or doctrine-of-equivalents coverage)
- invalidity (anticipation, obviousness, indefiniteness, lack of enablement)
- procedural defenses (standing, enforceability, scope of the asserted claims)
Court practice points:
Claim construction often determines the outcome more than the underlying fact pattern because most validity and infringement analyses depend on how terms are construed.
How does this case compare with other Celgene vs. generic challenges?
Featured snippet answer: Celgene’s litigation strategy in Hatch-Waxman typically emphasizes multiple patent categories to increase settlement leverage. Compared with narrower single-patent cases, multi-asset estates increase the probability that at least one asserted patent survives dispositive motions.
Competitive consequence: Even if one patent is invalidated, the remaining asserted patents can still block launch, delay damages calculations, or motivate settlement.
What settlements or injunctions are linked to 2:18-cv-17463?
A settlement or injunction outcome must be sourced from the docket record or court orders. Those specifics are not present in the prompt.
What is the FDA regulatory posture connected to this litigation?
Hatch-Waxman suits map to:
- the generic’s ANDA approval status and labeling
- patent certification timing (paragraph IV)
- whether exclusivity or stays are active
Material regulatory levers:
- 30-month stay
- changes to labeling for method-of-use patents
- potential design-around formulation or process changes
Key Takeaways
- The docket number 2:18-cv-17463 identifies a Hatch-Waxman patent infringement litigation between Celgene and Hetero filed in 2018 in the District of New Jersey.
- The case’s economic impact turns on the specific Orange Book patents asserted, the court’s claim construction, and dispositive validity/infringement rulings.
- Without the complaint’s asserted patent list and the docket’s adjudication/settlement orders, the litigation outcome and patent-asset strength cannot be mapped into a defensible, patent-by-patent analysis.
FAQs
- How do I determine which Orange Book patents are asserted in a specific Hatch-Waxman case like 2:18-cv-17463?
- What does a Paragraph IV filing imply about the 30-month stay and generic launch timing?
- When does claim construction usually determine infringement and validity outcomes in ANDA litigation?
- How do method-of-use patents affect labeling carve-outs and FDA approval in Celgene-style disputes?
- What settlement terms are most common in brand vs. generic patent suits involving multiple asserted patents?
References (APA)
No sources were provided in the prompt to cite.
